074 Early australian experience with erenumab for chronic migraine

OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm

OnabotulinumtoxinA (OnabotA) was approved for treatment of chronic migraine (CM) after publication of PREEMPT trials. Thus, we set out to evaluate the efficacy of OnabotA in a series of patients with CM treated according to the PREEMPT protocol. In May 2012 we began to offer OnabotA to patients with CM who did not respond to topiramate and at least one other preventive therapy (beta blocker and...

Chronic migraine.

Chronic migraine is a disabling neurologic condition that affects 2% of the general population. Patients with chronic migraine have headaches on at least 15 days a month, with at least eight days a month on which their headaches and associated symptoms meet diagnostic criteria for migraine. Chronic migraine places an enormous burden on patients owing to frequent headaches; hypersensitivity to v...

Combination therapy for chronic migraine

Neurology 2012;78:940–941 Chronic migraine (CM) is a frequent and challenging condition for practicing neurologists. It affects around 2% of adults and its prevalence in middleaged women reaches 5%.1 Management of CM is generally unsatisfactory and largely not evidencebased, in part because until recently CM has not been considered a true entity, but mostly a consequence of analgesic overuse. E...

Progress report. Aspirin in chronic gastric ulcer: an Australian experience.

[Progression from episodic migraine to chronic migraine].

Migraine is, essentially, an episodic disease. However, characteristics of headache of some episodic migraine change like as tension-type headache and number of headache days also increased, as a result, develop into chronic migraine.However, it is difficult to distinguish chronic migraine and medication oversuse headache. For this reason, and because of the general rule, The international Clas...